CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer-Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data

被引：2
|
作者：
Guarneri, V.
Frassoldati, A.
Cagossi, K.
Bottini, A.
Michelotti, A.
Cavanna, L.
Jovic, G.
Piacentini, F.
Oliva, C.
Conte, P. F.
机构：
[1] Modena Univ Hosp, Modena, Italy
[2] Ramazzini Hosp, Carpi, Italy
[3] Ist Ospitalieri, Cremona, Italy
[4] St Chiara Univ Hosp, Pisa, Italy
[5] Hosp Piacenza, Piacenza, Italy
[6] GlaxoSmithKline, Greenford, Middx, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：1
相关论文
共 47 条
  • [21] Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study
    Frassoldati, A.
    Guarneri, V.
    Bottini, A.
    Cagossi, K.
    Cavanna, L.
    Bisagni, G.
    Jovic, G.
    Piacentini, F.
    Oliva, C.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Real-World data of triplet combination of trastuzumab, lapatinib and chemotherapy in HER2-positive metastatic breast cancer: A multi-center retrospective study
    Li, Y.
    Gong, C.
    Lu, Q.
    Zhou, Z.
    Luo, T.
    Li, W.
    Li, G.
    Ge, R.
    Wang, B.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S66 - S66
  • [23] Gene-Set Enrichment Analysis (GSEA) of Microarray Data in Patients with HER2-Positive Breast Cancer Treated with Preoperative Chemotherapy Including Trastuzumab
    Shimizu, C.
    Mogushi, K.
    Tamura, K.
    Koizumi, F.
    Ando, M.
    Kinoshita, T.
    Tanaka, H.
    Fujiawara, Y.
    CANCER RESEARCH, 2009, 69 (24) : 591S - 591S
  • [24] TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Niravath, Polly
    Wang, Tao
    Rexer, Brent N.
    Forero, Andres
    Wolff, Antonio C.
    Nanda, Rita
    Storniolo, Anna M.
    Krop, Ian
    Goetz, Matthew P.
    Nangia, Julie R.
    Jiralerspong, Sao
    Pavlick, Anne
    Veeraraghavan, Jamunarani
    De Angelis, Carmine
    Gutierrez, Carolina
    Schiff, Rachel
    Hilsenbeck, Susan G.
    Osborne, C. Kent
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 821 - 827
  • [25] Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
    Bonnefoi, H.
    Jacot, W.
    Saghatchian, M.
    Moldovan, C.
    Venat-Bouvet, L.
    Zaman, K.
    Matos, E.
    Petit, T.
    Bodmer, A.
    Quenel-Tueux, N.
    Chakiba, C.
    Vuylsteke, P.
    Jerusalem, G.
    Brain, E.
    Tredan, O.
    Messina, C. G. M.
    Slaets, L.
    Cameron, D.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 325 - 332
  • [26] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [27] Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study
    Canino, Fabio
    Barbolini, Monica
    De Giorgi, Ugo
    Fontana, Tommaso
    Gaspari, Valeria
    Gianni, Caterina
    Gianni, Lorenzo
    Maestri, Antonio
    Minichillo, Santino
    Moscetti, Luca
    Mura, Antonella
    Nicoletti, Stefania Vittoria Luisa
    Omarini, Claudia
    Pagani, Rachele
    Sarti, Samanta
    Toss, Angela
    Zamagni, Claudio
    Costantini, Riccardo Cuoghi
    Caggia, Federica
    Antonelli, Giuseppina
    Baglio, Federica
    Belluzzi, Lorenzo
    Martinelli, Giulio
    Natalizio, Salvatore
    Ponzoni, Ornella
    Dominici, Massimo
    Piacentini, Federico
    BMC CANCER, 2024, 24 (01)
  • [28] Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial
    Canino, F.
    Barbolini, M.
    De Giorgi, U.
    Dominici, M.
    Gianni, L.
    Moscetti, L.
    Omarini, C.
    Zamagni, C.
    Molinaro, A.
    Antonelli, G.
    Baglio, F.
    Martinelli, G.
    Natalizio, S.
    Ponzoni, O.
    Piacentini, F.
    BREAST, 2023, 68 : S60 - S60
  • [29] Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer
    Piccart, Martine
    Procter, Marion
    Fumagalli, Debora
    de Azambuja, Evandro
    Clark, Emma
    Ewer, Michael S.
    Restuccia, Eleonora
    Jerusalem, Guy
    Dent, Susan
    Reaby, Linda
    Bonnefoi, Herve
    Krop, Ian
    Liu, Tsang-Wu
    Pienkowski, Tadeusz
    Toi, Masakazu
    Wilcken, Nicolas
    Andersson, Michael
    Im, Young-Hyuck
    Tseng, Ling-Ming
    Lueck, Hans-Joachim
    Colleoni, Marco
    Monturus, Estefania
    Sicoe, Mihaela
    Guillaume, Sebastien
    Bines, Jose
    Gelber, Richard
    Viale, Giuseppe
    Thomssen, Christoph
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Preliminary results of a phase II trial evaluating efficacy or safety of Trastuzumab plus Vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression
    Durando, Xavier
    Bachelot, Thomas
    Mauriac, Louis
    Delcambre, Corinne
    Maillart, Philippe
    Veyret, Corinne
    Jacquin, Jean -Philippe
    Mouret-Reynier, Marie-Ange
    Van Praagh, Isabelle
    Chollet, Philippe
    CANCER RESEARCH, 2009, 69
12345